Lv1
60 积分 2025-12-05 加入
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
7个月前
已完结
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
8个月前
已完结
Tertiary lymphoid structures in anticancer immunity
8个月前
已完结
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study
9个月前
已完结
皖公网安备34019202002308
